ASH 2023 | Taking into account CV events as patients with hematological malignancies are treated long-term

Daniel Addison • 15 Dec 2023

ASH 2023

General

As patients with hematological malignancies are being treated long-term, there is a need to take into account cardiovascular (CV) adverse events (AEs), which may occur as a result of cancer treatment and lead to increased mortality risk. Daniel Addison, MD, The Ohio State University Wexner Medical Center, Columbus, OH, highlights that CV AEs may impact the ability to continue long-term cancer therapy and may interact with therapies in ways that are yet poorly understood. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.